Status:
UNKNOWN
Graft Patency of QFR-guided Versus Angio-guided Coronary Artery Bypass Grafting
Lead Sponsor:
Beijing Anzhen Hospital
Collaborating Sponsors:
Beijing Municipal Science & Technology Commission
Conditions:
Coronary Artery Disease
Ischemic Heart Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Coronary artery bypass grafting(CABG) is the golden standard for severe coronary artery disease(CAD), the current surgery strategy is mainly based on coronary angiography(CAG), but many trials of PCI ...
Detailed Description
CABG is the major treatment of three vessels or left main disease. CAG is the main basis on choosing the vessels to graft, however, some of the grafts occluded shortly after surgery due to competitive...
Eligibility Criteria
Inclusion
- patients with evidence of angina pectoris
- left main or three vessels disease, have the indication for CABG after discussion of the heart team
- at least one main vessels stenosis on 40%-70%
Exclusion
- former cardiac surgery patients
- need to perform other cardiac or major surgery( i.e. valve surgery, carotid endarterectomy
- emergent CABG
- acute myocardial infarction time less than 7 days
- life expectancy less than 3 years
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2020
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT03770520
Start Date
February 1 2017
End Date
August 30 2020
Last Update
December 11 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029